PMID- 31996492
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20221207
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
VI  - 67
IP  - 4
DP  - 2020 Apr 28
TI  - Analysis of the effect of liraglutide on glycemic variability in patients with 
      type 2 diabetes.
PG  - 455-468
LID - 10.1507/endocrj.EJ19-0530 [doi]
AB  - The efficacy of liraglutide in the treatment of glycemic variability in type 2 
      diabetic patients remains to be fully elucidated. Some studies evaluated the 
      efficacy and safety of liraglutide in glycemic variability, and this 
      meta-analysis was performed to evaluate the accuracy of the results of existing 
      studies on the efficacy of liraglutide. We conducted a comprehensive search for 
      all relevant studies published in PubMed, EMBASE, Cochrane Library, and China 
      Academic Journal Full-Text Database from the beginning of 2011 to October 31, 
      2019. The mean +/- SD and 95% confidence interval were used for evaluation, and 
      subgroup and sensitivity analysis were carried out. Publication bias was 
      estimated by funnel plots and Egger's tests. A total of 16 studies were included 
      in the meta-analysis involving 492 participants. MAGE (mean amplitude of glycemic 
      excursion), LAGE (largest amplitude of glycemic excursions), SD (standard 
      deviation of blood glucose), and MODD (mean of daily differences) were collected 
      to reflect the variability of blood glucose. The glycemic variability indexes of 
      patients before and after treatment with liraglutide were compared. Patients with 
      treatment had lower glycemic variability compared with patients receiving 
      treatment of liraglutide. Compared with the patients before the treatment, the 
      patients after the treatment had a smaller glycemic variability (MAGE: I(2) = 
      92%, p < 0.01, Z = 11.91, p < 0.01, MD = -2.78, 95%CI: -3.24 - -2.32; LAGE: I(2) 
      = 76%, p = 0.08, Z = 9.94, p < 0.01, MD = -2.20, 95%CI: -2.59 - -1.81; MODD: I(2) 
      = 74%, p = 0.002, Z = 14.03, p < 0.01, MD = -0.90, 95%CI: -1.02 - -0.77; SD: I(2) 
      = 93%, p < 0.01, Z = 3.62, p < 0.01, SMD = -1.77, 95%CI: -2.73 - -0.81). 
      Sensitivity analysis showed that our results were reliable and no evidence of 
      significant publication bias was detected. The results of this study suggest that 
      patients with type 2 diabetes treated with liraglutide are associated with lower 
      glycemic variability.
FAU - Xing, Yuling
AU  - Xing Y
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang 050017, China.
AD  - Graduate School of Hebei Medical University, Shijiazhuang 050017, China.
FAU - Chen, Jinhu
AU  - Chen J
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang 050017, China.
FAU - Zhao, Liying
AU  - Zhao L
AD  - Graduate School of Hebei Medical University, Shijiazhuang 050017, China.
FAU - Ma, Huijuan
AU  - Ma H
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang 050017, China.
AD  - Hebei Key Laboratory of Metabolic Diseases, Hebei General Hospital Shijiazhuang, 
      Hebei 050051, China.
AD  - Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei 
      050017, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20200128
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Biological Variation, Individual
MH  - Blood Glucose/*metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Glycated Hemoglobin/metabolism
MH  - Glycemic Control
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Liraglutide/*therapeutic use
OTO - NOTNLM
OT  - Glycemic variability
OT  - Liraglutide
OT  - Meta-analysis
OT  - Type 2 diabetes
EDAT- 2020/01/31 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/01/31 06:00
PHST- 2020/01/31 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
PHST- 2020/01/31 06:00 [entrez]
AID - 10.1507/endocrj.EJ19-0530 [doi]
PST - ppublish
SO  - Endocr J. 2020 Apr 28;67(4):455-468. doi: 10.1507/endocrj.EJ19-0530. Epub 2020 
      Jan 28.